Cargando…

BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer

Colon and rectal cancer (CRC) are the third most common cancer in the United States and cause approximately 50,000 deaths per year. The anti–epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab (Erbitux®) and panitumumab (Vectibix®) have been recently introduced to treat CRC. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lea, Andrew, Allingham-Hawkins, Diane, Levine, Susan
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Evidence on Genomic Tests
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957244/ https://www.ncbi.nlm.nih.gov/pubmed/20972475 http://dx.doi.org/10.1371/currents.RRN1187

Ejemplares similares

DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform
por: Allingham-Hawkins, Diane, et al.
Publicado: (2010)

KIF6 p.Trp719Arg Testing to Assess Risk of Coronary Artery Disease and/or Statin Response
por: Allingham-Hawkins, Diane, et al.
Publicado: (2010)

ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer
por: Allingham-Hawkins, Diane, et al.
Publicado: (2010)

Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation
por: Zaharie, Florin, et al.
Publicado: (2015)

Genetic Testing for Lynch Syndrome in Individuals Newly Diagnosed with Colorectal Cancer to Reduce Morbidity and Mortality from Colorectal Cancer in Their Relatives
por: Coates, Ralph, et al.
Publicado: (2011)

KRAS mutational analysis for colorectal cancer: Application: Pharmacogenomic
por: Wang, Grace, et al.
Publicado: (2010)

Fecal DNA testing for Colorectal Cancer Screening: the ColoSure™ test
por: Ned, Renée M., et al.
Publicado: (2011)

BRAF Non-V600 Mutations in Metastatic Colorectal Cancer
por: Liu, Junjia, et al.
Publicado: (2023)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Oncotype DX tumor gene expression profiling in stage II colon cancer: Application: Prognostic, risk prediction
por: Webber, Elizabeth M., et al.
Publicado: (2010)

Tumor Gene Expression Profiling in Women with Breast Cancer: Test Category: Prognostic
por: Bellcross, Cecelia, et al.
Publicado: (2010)

PLoS Currents: Evidence on Genomic Tests – At the Crossroads of Translation
por: Gwinn, Marta, et al.
Publicado: (2010)

CYP2D6 testing to predict response to tamoxifen in women with breast cancer: Pharmacogenomic
por: Dahabreh, Issa, et al.
Publicado: (2010)

Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: Test Category: Pharmacogenomic (Treatment)
por: Grossniklaus, Daurice
Publicado: (2010)

A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors
por: Dancik, Garrett, et al.
Publicado: (2011)

Interleukin-28B genotype testing to determine response to the combination of pegylated-interferon and ribavirin for the treatment of hepatitis C virus
por: Nguyen, Christine M., et al.
Publicado: (2011)

Genetic risk profiling for prediction of type 2 diabetes
por: Mihaescu, Raluca, et al.
Publicado: (2011)

Use of Epidermal Growth Factor Receptor Mutation Analysis in Patients with Advanced Non-Small-Cell Lung Cancer to Determine Erlotinib Use as First-Line Therapy
por: Ishibe, Naoko, et al.
Publicado: (2011)

Use of Oncotype DX in Women with Node-Positive Breast Cancer
por: Ishibe, Naoko, et al.
Publicado: (2011)

Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk
por: Nguyen, Christine M., et al.
Publicado: (2011)

Cascade Screening for Familial Hypercholesterolemia (FH)
por: Ned, Renée M., et al.
Publicado: (2011)

Genetic Testing for CYP450 Polymorphisms to Predict Response to Clopidogrel: current evidence and test availability: Application: Pharmacogenomics
por: Ned, Renée M.
Publicado: (2010)

Comprehensive Carrier Screening and Molecular Diagnostic Testing for Recessive Childhood Diseases
por: Kingsmore, Stephen
Publicado: (2012)

BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
por: Terasawa, Teruhiko, et al.
Publicado: (2011)

HLA-B*5701 testing to predict abacavir hypersensitivity
por: Ma, Joseph D., et al.
Publicado: (2010)

Multi-marker Solid Tumor Panels Using Next-generation Sequencing to Direct Molecularly Targeted Therapies
por: Marrone, Michael, et al.
Publicado: (2014)

Analytical and Clinical Validity Study of FirstStepDx PLUS: A Chromosomal Microarray Optimized for Patients with Neurodevelopmental Conditions
por: Hensel, Charles, et al.
Publicado: (2017)

The yin–yang of kinase activation and unfolding explains the peculiarity of Val600 in the activation segment of BRAF
por: Kiel, Christina, et al.
Publicado: (2016)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

Contemporary treatment approaches for metastatic colorectal cancer driven by BRAF V600 mutations
por: Kanat, Ozkan, et al.
Publicado: (2020)

The Evolutionary Landscape of Treatment for BRAF(V600E) Mutant Metastatic Colorectal Cancer
por: Mauri, Gianluca, et al.
Publicado: (2021)

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
por: Guerrero, Rodrigo Motta, et al.
Publicado: (2022)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Intratumor morphologic and transcriptomic heterogeneity in (V600E)BRAF-mutated metastatic colorectal adenocarcinomas
por: Angerilli, V., et al.
Publicado: (2021)

Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2022)

The expanding phenotype of hypokalemic periodic paralysis in a Japanese family with p.Val876Glu mutation in CACNA1S
por: Kurokawa, Mari, et al.
Publicado: (2020)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
por: Xu, Ting, et al.
Publicado: (2022)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

BRaf(V600E) cooperates with Pten silencing to elicit metastatic melanoma
por: Dankort, David, et al.
Publicado: (2009)

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma
por: Ponti, Giovanni, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_e35prajljt8ar1mf18925rbqjm